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Abstract Structure-based rug design requires the development 
of efficient computer programs for exploring the structural 
compatibility of various flexible ligands with a given receptor. 
While various algorithms are available for finding docked 
conformations, electing a target function that can reliably score 
the conformations remains a serious problem. We show that the 
use of an empirical free energy evaluation method, originally 
developed to characterize protein-protein interactions, can 
substantially improve the efficacy of search algorithms. In 
addition to the molecular mechanics interaction energy, the 
function takes account of solvation and side chain conforma- 
tional entropy, while remaining simple enough to replace the 
incomplete target functions used in many drug docking and 
design procedures. The free energy function is used here in 
conjunction with a simple site mapping-fragment assembly 
algorithm, for docking the MVT-101 non-peptide inhibitor to 
HIV-1 protease. In particular, we predict the bound structure 
with an all atom RMSD of 1.21 A, compared to 1.69 A using an 
energy target function, and also accurately predict the free 
energy shifts obtained with a series of five trimeric hydro- 
xyethylene isostere analogs. 
Key words: Free energy method; Free energy mapping; 
Protein-ligand ocking and design; HIV-1 protease inhibitor 
1. Introduction 
The ability to limit the ways in which a putative ligand 
might bind a known receptor site is crucial to the success of 
structure-based drug design [1]. Automated ocking methods 
position the ligand and receptor molecules together in many 
different ways and then 'score' each configuration according 
to a target function [2,3]. The main issues in developing com- 
putational tools for docking are the selection of an efficient 
search algorithm, and the choice of a target function that can 
reliably identify the most likely conformations of the ligand- 
receptor complex [1,4]. 
The number of search algorithms used in docking is explod- 
ing, with methods ranging from the simple but very successful 
geometric search in the DOCK program [5] to various com- 
binatorial [6-8], Monte Carlo [9-13], and genetic [14,15] algo- 
rithms. Another large class of methods is based on the site 
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peptide inhibitor MVT-101 with sequence Ace-Thr-Ile-Nle-W[CH2- 
NH]-Nle-Gln-Arg-amide, where Nle represents norleucine and Ace is 
N-acetyl. 
mapping-fragment assembly strategy [16] used in a variety of 
programs [17-23]. The basic idea is to construct maps of the 
binding site by placing individual functional groups on a grid, 
and determining the most favorable positions. These positions 
are then used to build entire ligand molecules in the assembly 
stage of the procedure. A variety of drug design programs 
based on this principle have been developed. 
While a large number of search strategies are available, the 
development of an effective target function remains a major 
obstacle to achieving automatic and reliable procedures for 
docking and design [1,4]. The ideal target function would be 
the binding free energy. However, computationally intensive 
free energy evaluation through free energy perturbation and 
thermodynamic integration techniques [24] is not viable, and 
hence at present docking and design are based on the use of 
simplified target functions such as shape complementarity, 
electrostatic or total interaction energy [25]. These are useful 
under certain conditions, but are generally unable to correctly 
rank the docked conformations, largely because they fail to 
properly account for solvation and entropy change [26]. 
Here we present results indicating that the use of a recently 
introduced empirical binding free energy function [27] can 
substantially improve the accuracy and efficiency of site map- 
ping and fragment assembly algorithms in docking and de- 
sign. Although results are presented only for the HIV-1 pro- 
tease inhibitor MVT-101 and for five hydroxyethylene isostere 
analogs, the free energy evaluation model is general and has 
been applied to a variety of other systems [28]. The example 
shown here demonstrates that, starting with the structural 
motif seen in other peptide-based protease inhibitors, MVT- 
101 can be docked to within 1.21 A all atom RMSD (root- 
mean square deviation) from the crystal structure. For com- 
parison, the same procedure with a target function based on 
the CHARMm energy (i.e., neglecting solvation and entropic 
effects) yields a structure with 1.69 ,~ RMSD. We also show 
that starting with predicted structures of the HIV-1 
PR[AbaA69,A97,B69,B97]-MVT-101 [29] inhibitor complex, the 
free energy correctly rank orders five trimeric hydroxyethylene 
isostere analogs. 
2. Methods 
2.1. Free energy evaluation 
The binding free energy, AG, is written as a sum of the various free 
energy contributions 
AG = ~rr~ +(AGh) + (AE1)--TASsc--TASbb + const (1) 
where E~r ~ is the electrostatic interaction energy between the receptor 
and the ligand, and (AEI) is the difference in the internal energy of the 
ligand between its bound (E~l) and free (5) states. The operation (...) 
denotes Boltzmann-weighted averaging over an appropriate sample of 
free ligand conformations. The terms TASte and TASbb represent con- 
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Table 1 
Site mapping with the free energy target function (Eq. 2); positions with the lowest and second lowest values of the target function for each re- 
sidue 
Res. Rot. a Translation (A) Rotation (degrees) RMSD (,~) 
x y z x y z Mapped b Final c 
Thrl 1 0.0 0.3 0.0 0.0 -30.0 0.0 1.78 - 
Thrl 2 0.0 0.3 0.0 0.0 -30.0 0.0 1.26 1.32 
Ile2 3 0.3 0.0 0.0 0.0 0.0 0.0 1.51 1.00 
Ile2 3 0.0 0.3 0.0 0.0 0.0 -30.0 1.79 
Nlez 1 0.0 -0 .3  0.0 0.0 0.0 0.0 1.10 
Nle3 1 -0.3 0.0 0.0 0.0 0.0 0.0 1.06 0.77 
Nle4 1 0.0 0.0 -0.3 -30.0 0.0 0.0 1.68 - 
Nle4 1 0.0 0.0 -0.3 0.0 0.0 -30.0 1.70 2.03 
Gln~ 4 0.0 0.0 -0.3 0.0 30.0 0.0 1.29 1.19 
Gln5 4 0.0 -0.3 0.0 0.0 30.0 0.0 1.24 - 
Arg6 2 0.0 -0.3 0.0 0.0 0.0 0.0 1.29 - 
Arg6 2 0.0 0.0 -0.3 0.0 0.0 0.0 1.08 0.61 
aNumber of rotamer as listed by Ponder and Richards [39]. Rotamers for Met were used for Nle3 and Nle4. 
bAll atom RMSD between the best mapped position of the individual residue, and the corresponding conformation i the X-ray structure of MVT- 
101 [291. 
CAll atom RMSD between the residue in the best docked conformation following concatenation, and the corresponding conformation i the X-ray 
structure of MVT-101 [29]. 
tributions to the free energy due to the loss of side chain (sc) and 
backbone (bb) entropy. (AGh) represents the hydrophobic ontribu- 
tion to the binding free energy and is defined as 
(A~,) = AG~i-(AG~)-(AG~) 
where the terms on the right hand side denote free energies of transfer 
from water into a (partially) nonpolar environment (in this paper 
octanol), and the superscripts rl, r, and 1 indicate the receptor-ligand 
complex, the free receptor, and the free ligand, respectively. (hCh) and 
(AC~h) are Boltzmann-weighted averages over the free states. Finally, 
'const' is a number (9 kcal/mol) that is independent of the details of 
the interaction, and reflects the loss of rotational, vibrational and 
cratic free energies. 
The origin and testing of this function were discussed extensively in
Vajda et al. [27]. Briefly, the hydrophobic free energy change is eval- 
uated using a modified Eisenberg-McLachlan tomic solvation param- 
eter model [30]; the electrostatic term using a Coulombic expression 
with CHARMm parameters; and the conformational entropy term by 
scaling the side chain entropy losses listed by Pickett and Sternberg 
[31]. Prior to free energy evaluation, all van der Waals clashes are 
removed with an energy minimization protocol. The model assumes 
that the solute-solute interface is as well packed as the solute-solvent 
interface; i.e., the van der Waals interactions lost when the ligand and 
receptor are separated, are compensated by van der Waals interac- 
tions gained between the exposed surfaces and the solvent, and hence 
the total change in the van der Waals interactions is small. This 
assumption, used in a number of semi-empirical free energy functions 
[32,33], is clearly violated by packing defects, and provides only a 
first-order approximation. Nevertheless, it is better than restricting 
considerations to protein-ligand interaction energy, and thereby ne- 
glecting all interactions with the solvent. 
Free energy terms that do not vary from one bound conformation 
to another need not be considered in docking, and hence the target 
functions becomes 
O=-AG-(AE1) + TASbb--const + (AG[~) + <AGI, ) -- 
= E~d + AG~' + Eb--TAS~o (2) 
For comparison we repeat he calculations with the traditional target 
function of the form 
OCHARMm = Erl + E~ (3) 
where Erl is the CHARMm interaction energy between the receptor 
and the ligand, and E~I is the CHARMm conformational energy of the 
ligand. The interaction energy consists of electrostatic and van der 
Waals terms, whereas the conformational energy also includes bond 
angle, bond length, dihedral and improper angle energies [34]. 
For the calculation of target functions of trimeric analogs in which 
the central side chains are substituted, we will always use the back- 
bone of the three central residues of the docked MVT-101 inhibitor. 
Since we are interested only in target function differences when we 
compare analogs, the internal energy E~I will cancel. We also take the 
backbone conformational entropy of the free trimers to be the same. 
Hence for comparing analogs, we need only evaluate 
= E~ + AG~a--TASsc (4) 
and 
~'~CHARMm : Erl (5) 
2.2. Docking the MVT-IO1 inhibitor to HIV-1 protease 
Protease bound peptide-based inhibitors have a well-defined struc- 
tural motif, and structural conservation is even stronger within a 
particular class of proteases. For example, the calculated a-carbon 
RMSD is 0.56 A. for HIV-1 protease inhibitors MVT-101 [29], JG- 
365 [35], U-85548e [36], A-74704 [37], and acetylpepstatin [38]. This 
strong overall backbone homology reduces the search space consider- 
ably and suggests that a very simple search algorithm should be ef- 
fective. 
The free energy of the receptor is mapped by translating and rotat- 
ing individual amino acid residues with each side chain conformation 
from the rotamer library of Ponder and Richards [39]. We allow 
limited C ~ movement (+ 0.3 A along each axis) and limited reorienta- 
tion of the 6~-C ¢ bond (+ 30 ° about each axis). The procedure yields 
49 possible translational/rotational positions for each rotamer. The 
origin in all translations and rotations corresponds to the c~-carbon 
positions from the crystal; however, the rotamer conformations used 
are different from the crystal, thus avoiding the imposition of bias. 
For each state thus obtained (49 × the number of rotamers for a given 
side chain), the probe-receptor system is subjected to 120 steps of 
CHARMm minimization, in order to define a space that avoids steric 
clashes, and the target function is evaluated. The parameters used 
throughout in all steps are a distance dependent dielectric onstant 
(4r), a non-bonded cutoff of 17.0 A, and mass-weighted harmonic 
constraints of 20 kcal/molL~  on atomic positions. The mapping pro- 
cedure creates a list of favorable positions and conformations for each 
residue, ranked according to its free energy of binding to the receptor. 
The sequence of MVT-101, with the number of rotamers used for 
each residue, is as follows: Thr(2), Ile(3), Nle(3), Nle(3), Gln(6), and 
Arg(5). In spite of the small rotamer library [39] and the limited 
number of translations and rotations, the combinations of discrete 
states result in about 2.24× 10 l° conformations. Several procedures 
short of an exhaustive search, which is not feasible, can be used to 
generate complete structures from the mapping data, including ex- 
tended dynamic programming methods [8]. Here we select only the 
two best states for each side chain, giving a total of  64 structures for 
the 6 residue long inhibitor. Prior to free energy evaluation, the energy 
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Table 2 
Site mapping with the CHARMm energy target function (Eq, 3); positions with the lowest and second lowest values of the target function for 
each residue 
Res. Rot? Translation (,A) Rotation (degrees) RMSD (,~) 
x y z x y z Mapped a FinaP 
Thrl 2 0.0 0.0 0.3 0.0 0.0 0.0 0.33 1.24 
Thrl 2 0.0 -0.3 0.0 0.0 -30.0 0.0 1.28 - 
Ile2 1 0.0 0.3 0.0 0.0 30.0 0.0 1.66 
Ile2 1 0.3 0.0 0.0 0.0 30.0 0.0 1.63 1.14 
Nle3 1 0.0 0.0 0.3 0.0 --30.0 0.0 0.97 0.92 
Nlea 1 0.0 -0.3 0.0 0.0 --30.0 0.0 0.97 - 
Nle4 2 0.3 0.0 0.0 0.0 0.0 --30.0 1.10 2.41 
Nle4 2 0.0 0.3 0.0 0.0 0.0 -30.0 0.98 - 
Gln5 3 0.0 0.0 0.3 0.0 0.0 30.0 2.26 2.17 
Gln~ 3 -0.3 0.0 0.0 0.0 0.0 30.0 2.47 - 
Arg6 2 -0.3 0.0 0.0 -30.0 0.0 0.0 1.85 
Arg6 2 0.0 0.0 0.3 -30.0 0.0 0.0 1.92 1.72 
aNumber of rotaAs described in Table 1. 
of each of the 64 structures i minimized with a mass-weighted har- 
monic constraint of 20 kcal/mol/A, 2 for 200 steps to remove possible 
steric clashes and strains that can arise during concatenation. I  order 
to provide a frame of reference for comparison, 100 additional struc- 
tures were generated by randomly selecting a conformation from the 
mapping data for each of the 6 residues. In particular, a rotamer for 
the residue was randomly selected, then one of the translational/rota- 
tional positions was randomly chosen. Following concatenation, the 
minimization and free energy evaluation procedure, explained above, 
was repeated for each of the 100 structures. 
As a further test, we repeated the entire calculation (i.e., both the 
mapping of the site and the construction of 64 'best' structures), using 
the CHARMm energy target function defined by Eq. 3 instead of the 
free energy target function defined by Eq. 2. 
2.3. Free energy evaluation of hydroxyethylene isostere inhibitor analogs 
In a related calculation, we evaluated the binding free energies for 
five trimeric hydroxyethylene isostere analogs, for which inhibition 
constants were measured by Dreyer et al. [40]. The structures of the 
five trimeric inhibitor analogs with sequences (Boc)Phe-(CH2)X- 
Val(NH2), where X =Gly, Ala, Npr, Ile, and Phe, were generated 
by homologous extension, starting with the MVT-101 structure that 
minimized the free energy target function. The substitutions were 
carried out with the QUANTA protein design tool, which maximally 
overlaps the common atoms of the new side chain with those of the 
template side chain [41]. Each structure was minimized for a total of 
120 steps subject o a mass-weighted harmonic onstraint of 20 kcal/ 
2 mol/A , and then the free energy was evaluated. 
The calculations were repeated with the CHARMm energy target 
function, starting with the MVT-101 structure that minimized the 
same CHARMm target function. Since the substitution of Phe at 
position P3 results in steric clashes that are not completely removed 
by the constrained minimization, we do not constrain the atoms at 
this position. After minimization, the target function was calculated 
according to Eq. 3. 
3. Results and discussion 
3.1. Docking the MVT-101 inhibitor to HIV-1 protease 
Sixty-four structures for MVT-101 were constructed by 
concatenating the two lowest energy conformations at each 
position (Tables 1 and 2). To provide perspective on the range 
of RMSD possibilities, we generated an additional 100 struc- 
tures obtained by concatenating randomly selected states for 
different residues using the free energy target function• The 64 
MVT-101 structures obtained by concatenating and refining 
the two lowest free energy structures have all atom RMSDs 
from the minimized crystal structure, ranging from 1.15 A to 
1.57 A with an average of 1.36 A (Fig. 1). By contrast, the 
RMSDs of the additional 100 structures obtained by combin- 
ing randomly selected conformations, ranged from 1.47 ,~ to 
2.93 A with an average of 2.24 ,~. Only 7 of these had RMSD 
values within the range of those chosen by free energy. The 64 
structures generated with the CHARMm target function, 
dxbCHARMm , in both mapping and assembly stages of the algo- 
rithm, range from 1.53 .A to 1.78 A; have an average of 1.68 
A, and show no correlation between RMSD and target func- 
t ion value (Fig. 2). Specifically, there is a group of structures 
which have very low CHARMm energy, but a high RMSD 
range of 1.69 to 1.72 A. 
We also calculated the CHARMm objective function for 
the 64 structures generated using free energy, and found 
that CHARMm was able to rank these conformations almost 
as well as the free energy. However, as shown in Fig. 2, the 
CHARMm potential performs poorly in the mapping stage, 
and using only the two best mapped positions, the fragment 
assembly stage fails to yield any good conformation. In other 
words, the best positions found for the individual residues are 
substantially different from their positions in the X-ray struc- 
ture of the ligand if solvation and entropic effects are not 
taken into account. 
3.2. Design of hydroxyethylene &ostere inhibitor analogs 
The relation between InK/ for  five hydroxyethylene isostere 
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Fig. 1. Plot of free energy target function against the all atom 
RMSD from the minimized crystal for the 64 structures generated 
by concatenating the best and second best mapped residue positions 
(circles), and 100 structures generated by concatenation f randomly 
selected residue positions (crosses). 
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Table 3 
The free energy values, fL and total CHARMm interaction energies computed for the respective set of analogs constructed from MVT-101 
templates that had the lowest value of the target function 
Free energy target function 
X ~ AGh El~l TASsc ~'-2 b lnKi 
Gly -21.87 -1.91 5.41 -18.38 --11.94 
Ala -23.73 --2.00 5.61 -20.12 --15.16 
Npr --25.71 -2.12 6.71 -21.12 --16.81 
Ile -26.21 -2.20 6.68 --21.73 - 17.59 
Phe -27.57 - 1.98 6.60 -22.96 -20.39 
CHARMm energy target function 
c d Xa Ew)w E~LeC ~rrt lnKi 
Gly --24.18 -1.91 --26.10 -11.94 
Ala -26.73 -2.00 -28.73 - 15.16 
Npr -30.98 -2.12 -33.09 - 16.81 
Ile -28.89 -2.20 -31.08 - 17.59 
Phe -30.39 - 1.98 -30.37 -20.39 
~Inhibitors with sequence: (Boc)Phe-(CH2)X-VaI(NH2). 
bFree energy target function, Eq. 5. 
°Van der Waals component of the CHARMm interaction energy. 
dElectrostatic component of the CHARMm interaction energy. 
eCHARMm energy target function, Eq. 5. 
analogs, studied by Dreyer et al., and free energies calculated 
according to Eq. 2 for the structures estimated by homolo- 
gous extension are shown in Fig. 3 and listed in Table 3 [40]. 
Assuming the inhibition constants, Ki, were obtained under 
the quasi-equilibrium conditions of Michaelis-Menten kinetics 
[42,43], we expect a plot of AG against lnKi to be a straight 
line, with a slope given by the thermal energy, RT= 0.6 kcal/ 
mol (at 300 K). 
When free energy shifts are evaluated for the analogs, using 
the predicted structure as template, the slope is 0.80, and r 
exceeds 0.97 (Fig. 3, Table 3). When the CHARMm interac- 
tion energy is used, starting with its predicted structure as 
template (Fig. 3, Table 3), the slope is 1.03 and the correlation 
coefficient is 0.97. These results show that correct ranking of 
the analogs can be achieved with both traditional and free 
energy target functions. However, the use of free energy yields 
two substantial advantages. First, due to the assumed cance- 
lation of van der Waals terms, the free energy is a 'smooth 
function' providing well defined, reliable values that are not 
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Fig. 2. Plot of free energy target function (Eq. 2) versus all atom 
RMSD for the 64 structures generated by free energy mapping (cir- 
cles), and CHARMm energy target function (Eq. 3) versus all atom 
RMSD for the 64 structures constructed by CHARMm energy map- 
ping (solid squares). 
sensitive to small changes in the atomic coordinates. By con- 
trast, the value of the interaction energy is heavily affected by 
the details of calculation such as the termination condition in 
the minimization. Second, the spacing between analogs (i.e. 
the slope of the line in Fig. 3) is more accurate using free 
energy. Indeed, because what is measured (i.e., lnKi or 
plCs0) is related to the binding free energy, the correlation 
of the inhibition constant and interaction energy must be in 
error by some combination of solvation and entropy, which 
apparently varies from analog to analog. However, since the 
error does not vary greatly, an empirical correction is possi- 
ble. For example, Holloway et al. used a training set of 33 
inhibitor structures to relate calculated interaction energies 
(from the MM2X force field) to experimental inhibition con- 
stants [44]. This relation, which maps interaction energy into 
plC50 values, has been applied to 16 additional inhibitors. The 
correlation between predicted plC~0 values and measured in- 
hibition constants was 0.937, which must be considered good 
agreement. 
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Fig. 3. Plot of free energy target function and lnKi) with linear re- 
gression (circles and solid line) [slope = 0.80, r = 0.970], and the 
plot of the CHARMm interaction energy and lnKt with linear re- 
gression (squares and small dashed line), [slope = 1.03, r=0.967]. 
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